Oriva Therapeutics, a Spain-based women’s health biotechnology company, has appointed Dr Agnès Arbat as CEO.
Dr Arbat brings more than 25 years of experience in the pharmaceutical industry, with a strong track record across clinical development, medical affairs and commercial strategy in women’s health. During her career she has played a central role in over 20 clinical studies in women’s health. She has also contributed to the successful launch of more than 10 products including Nexplanon, Xarelto and Ventavis.
She was previously co-founder and CEO of Oxolife, a specialist biotech focused on female fertility, and before that led the Women’s Health and Cardiovascular medical team at Bayer and worked at Organon in Medical Affairs for Women’s Health.
Oriva was founded earlier this year with the support of Spain-based Asabys Partners and is now advancing its clinical-stage pipeline, which includes two advanced assets. Its lead asset is ORV-362, a first-in-class, non-hormonal, disease-modifying therapy for endometriosis. The second programme, ORV-499, is focused on the treatment of uterine fibroids.
“Dr Arbat’s deep scientific experience in women’s health and her strong track record of strategic leadership makes her exceptionally well qualified to lead Oriva as it advances its programmes and accelerates through its next phase of growth” said Clara Campàs, co-founder and managing partner at Asabys Partners.
